Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Valneva

- PMLiVE

Valneva’s chikungunya virus vaccine recommended by US CDC advisory committee

The mosquito-borne viral disease leads to symptomatic disease in 97% of people within a week or less following the mosquito bite

- PMLiVE

Valneva sells FDA priority review voucher for chikungunya vaccine for $103m

The company received a tropical disease PRV in November following the FDA’s approval of Ixchiq for the prevention of disease caused by chikungunya virus

- PMLiVE

Valneva’s chikungunya vaccine approved by FDA for adults at increased exposure risk

The decision makes Ixchiq, which is administered as a single injection, the world's first licensed vaccine against the mosquito-borne disease

dengue fever mosquito

Bavarian Nordic’s chikungunya vaccine candidate shows promise in late-stage trial

There is currently no approved vaccine or specific treatment for chikungunya virus infections

- PMLiVE

Valneva reports additional data for COVID-19 booster

VLA2001 was well tolerated in participants previously vaccinated with an mRNA vaccine

- PMLiVE

Valneva’s chikungunya vaccine candidate shows promise in antibody persistence trial

The trial results demonstrated a 99% seroresponse rate 12 months after a single-dose vaccination

- PMLiVE

Pfizer and Valneva report six-month antibody persistence data for Lyme disease vaccine

VLA15 is the only Lyme disease vaccine candidate currently in clinical development

- PMLiVE

Valneva actively discussing second-generation COVID-19 vaccine with prospective partner

The company also plans to send the remaining stocks of its current COVID-19 vaccine to international markets

- PMLiVE

WHO recommends Valneva’s COVID-19 vaccine for those aged between 18 to 50 years old

VLA2001 is a purified, inactivated, and adjuvanted whole virus SARS-CoV-2 vaccine, employing a similar approach to the flu vaccine

- PMLiVE

Valneva and Pfizer initiate phase 3 Lyme disease vaccine study

VLA15 is the only Lyme disease vaccine candidate currently in clinical development

- PMLiVE

Pfizer to buy 8.1% stake in Valneva in support of joint Lyme disease programme

VLA15 is the only Lyme disease vaccine candidate currently in clinical development

EU flag

EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine

The vaccine is currently the only inactivated, whole virus adjuvanted candidate in clinical trials in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links